News and Trends 17 Oct 2022
Positive results from Milestone Pharmaceuticals’ phase 3 PSVT trial
Milestone Pharmaceuticals Inc. has announced positive topline efficacy and safety data from the phase 3 RAPID clinical trial of etripamil, the company’s investigational calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT). “PSVT is an unpredictable, disruptive burden on patients, with current interventions restricted to the costly and inconvenient acute care setting,” said Bruce […]